Welcome to our dedicated page for Henry Schein news (Ticker: $HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Henry Schein's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Henry Schein's position in the market.
Henry Schein, Inc. reported solid first-quarter 2024 financial results with sales growth of 3.7%, GAAP diluted EPS of $0.72, and non-GAAP diluted EPS of $1.10. The company tightened its total sales growth guidance range to 8% to 10% and affirmed its 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16. Adjusted EBITDA growth is expected to be more than 15% in 2024.
Henry Schein, Inc. (Nasdaq: HSIC) will be presenting at several investor conferences in May 2024. The company will be presenting at the Bank of America Healthcare Conference in Las Vegas on May 14, Leerink Healthcare Crossroads Conference in Austin on May 29, and Stifel Jaws & Paws Conference in New York City on May 30. Presentations can be accessed via live webcast on the company's IR webcasts page. Replays will also be available on the Henry Schein website.
